Diadema Partners LP Makes New $2.21 Million Investment in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Diadema Partners LP purchased a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 131,862 shares of the company's stock, valued at approximately $2,209,000. Centessa Pharmaceuticals accounts for approximately 0.9% of Diadema Partners LP's holdings, making the stock its 23rd biggest position. Diadema Partners LP owned about 0.10% of Centessa Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares during the period. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares during the period. XTX Topco Ltd increased its holdings in shares of Centessa Pharmaceuticals by 122.9% during the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after purchasing an additional 12,506 shares in the last quarter. Finally, State Street Corp acquired a new position in Centessa Pharmaceuticals during the third quarter worth $777,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 11,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the transaction, the chief technology officer now directly owns 121,503 shares in the company, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,705,145.48. This trade represents a 5.39 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 213,824 shares of company stock valued at $3,530,601. 11.59% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating for the company. Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 target price for the company. Morgan Stanley restated an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $27.71.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock traded up $0.18 during trading hours on Friday, reaching $13.79. The company had a trading volume of 480,936 shares, compared to its average volume of 605,883. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -9.01 and a beta of 1.53. The stock has a fifty day moving average of $14.47 and a 200-day moving average of $15.88.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. On average, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.